Bio-Techne Corporation (TECH) DCF Valuation
Why we don't show a single “fair value” for TECH
Even the optimistic scenario of a conservative trailing-FCF model ($26.68) sits far below today's price — the market is paying for growth and durability beyond what this model structure captures. The honest lens is the question below: what growth does today's price actually require? The model scenarios are listed further down for reference.
What would today's price require?
$71.00 is justified only if free cash flow grows about +37.5% a year (fading to 2.5% long-run) at a 10.9% required return — faster than the company has actually grown.
| Scenario | FCF growth (fading to 2.5%) | Discount | Value / share |
|---|---|---|---|
| Conservative | 2.6%/yr | 11.9% | $16.02 |
| Base case | 5.6%/yr | 10.9% | $20.51 |
| Optimistic | 8.6%/yr | 9.9% | $26.68 |
| Analyst DCF (FMP) | independent reference — different model | $22.75 | |
Current Price
$71.00
Market-Implied Growth
+37.5%/yr
vs +3.7% 5Y actual
Base-Case Model Value
$20.51
model output — not a price target
TECH DCF Fair Value Calculator
Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for TECH (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.
Base inputs: FCF $246.3M · 0.16B shares · net debt $183.8M
Estimated Fair Value
$22.73
-68.0% vs $71.00
Sensitivity — fair value by discount rate × terminal growth
How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 5.6%/yr FCF growth and 10-year horizon fixed. Green = above today's $71.00; red = below. Your current case is outlined.
| WACC ↓ / Terminal → | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
|---|---|---|---|---|---|
| 8.9% | $28.02 | $29.26 | $30.68 | $32.35 | $34.33 |
| 9.9% | $24.30 | $25.17 | $26.16 | $27.30 | $28.61 |
| 10.9% | $21.37 | $22.01 | $22.73 | $23.53 | $24.45 |
| 11.9% | $19.03 | $19.50 | $20.03 | $20.62 | $21.28 |
| 12.9% | $17.10 | $17.47 | $17.87 | $18.31 | $18.80 |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman